GlaxoSmithKline (GB:GSK) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GlaxoSmithKline has announced successful phase III trial results for depemokimab, showing significant improvements in patients with chronic rhinosinusitis with nasal polyps. Depemokimab, which is administered biannually, has demonstrated a reduction in nasal polyp size and obstruction, and is part of GSK’s efforts to combat type 2 inflammation in various inflammatory conditions. These promising results are expected to support future regulatory filings for the drug, which is not yet approved.
For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.